Pfizer Acquires Exclusive Rights to Obesity Drug in China

Dow Jones

8 hours ago

By Tracy Qu

Pfizer has acquired exclusive rights to commercialize an obesity therapy in China in a deal worth up to $495 million.

The U.S. drugmaker reached an agreement with Hangzhou Sciwind Biosciences for ecnoglutide, a drug recently approved by Chinese regulators to treat diabetes, according to a statement posted on WeChat on Tuesday. The therapy is also under regulatory review for obesity treatment, the statement said.

The potential $495 million payment includes an upfront fee as well as regulatory and milestone payments, Sciwind said.

The collaboration with Sciwind "marks a significant milestone in accelerating Pfizer's long-term strategic footprint in the metabolic field," said Pfizer China president Jean-Christophe Pointeau in the statement.

Chinese biotech companies are increasingly partnering with overseas drugmakers. Earlier this month, Innovent Biologics announced a collaboration with Eli Lilly that includes up to $8.5 billion in milestone payments.

Write to Tracy Qu at tracy.qu@wsj.com

(END) Dow Jones Newswires

February 23, 2026 23:47 ET (04:47 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2613776611"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613776611\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613776611?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 12:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613776611","market":"sg","top_or_hot":-1,"title":"Pfizer Acquires Exclusive Rights to Obesity Drug in China","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Tracy Qu \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Pfizer has acquired exclusive rights to commercialize an obesity therapy in China in a deal worth up to $495 million. \n</p>\n<p>\n  The U.S. drugmaker reached an agreement with Hangzhou Sciwind Biosciences for ecnoglutide, a drug recently approved by Chinese regulators to treat diabetes, according to a statement posted on WeChat on Tuesday. The therapy is also under regulatory review for obesity treatment, the statement said. \n</p>\n<p>\n  The potential $495 million payment includes an upfront fee as well as regulatory and milestone payments, Sciwind said. \n</p>\n<p>\n  The collaboration with Sciwind \"marks a significant milestone in accelerating Pfizer's long-term strategic footprint in the metabolic field,\" said Pfizer China president Jean-Christophe Pointeau in the statement. \n</p>\n<p>\n  Chinese biotech companies are increasingly partnering with overseas drugmakers. Earlier this month, <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a> announced a collaboration with Eli Lilly that includes up to $8.5 billion in milestone payments. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Tracy Qu at tracy.qu@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 23, 2026 23:47 ET (04:47 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Acquires Exclusive Rights to Obesity Drug in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Acquires Exclusive Rights to Obesity Drug in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-24 12:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Tracy Qu \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Pfizer has acquired exclusive rights to commercialize an obesity therapy in China in a deal worth up to $495 million. \n</p>\n<p>\n  The U.S. drugmaker reached an agreement with Hangzhou Sciwind Biosciences for ecnoglutide, a drug recently approved by Chinese regulators to treat diabetes, according to a statement posted on WeChat on Tuesday. The therapy is also under regulatory review for obesity treatment, the statement said. \n</p>\n<p>\n  The potential $495 million payment includes an upfront fee as well as regulatory and milestone payments, Sciwind said. \n</p>\n<p>\n  The collaboration with Sciwind \"marks a significant milestone in accelerating Pfizer's long-term strategic footprint in the metabolic field,\" said Pfizer China president Jean-Christophe Pointeau in the statement. \n</p>\n<p>\n  Chinese biotech companies are increasingly partnering with overseas drugmakers. Earlier this month, <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a> announced a collaboration with Eli Lilly that includes up to $8.5 billion in milestone payments. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Tracy Qu at tracy.qu@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 23, 2026 23:47 ET (04:47 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999011175.SGD","symbol_name":"Nikko AM Global Dividend Equity Dis SGD-H","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2613776611","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613776611","pubTimestamp":1771908420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Pfizer has acquired exclusive rights to commercialize an obesity therapy in China in a deal worth up to $495 million.The U.S. drugmaker reached an agreement with Hangzhou Sciwind Biosciences for ecnoglutide, a drug recently approved by Chinese regulators to treat diabetes, according to a statement posted on WeChat on Tuesday. The therapy is also under regulatory review for obesity treatment, the statement said.The potential $495 million payment includes an upfront fee as well as regulatory and milestone payments, Sciwind said.The collaboration with Sciwind \"marks a significant milestone in accelerating Pfizer's long-term strategic footprint in the metabolic field,\" said Pfizer China president Jean-Christophe Pointeau in the statement.Chinese biotech companies are increasingly partnering with overseas drugmakers. Earlier this month, Innovent Biologics announced a collaboration with Eli Lilly that includes up to $8.5 billion in milestone payments.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","BK4592":"伊斯兰概念","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4550":"红杉资本持仓","BK4588":"碎股","BK4568":"美国抗疫概念","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4007":"制药","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999002232.USD":"Allianz Global High Payout USD","PFE":"辉瑞","BK4599":"减肥药","BK4581":"高盛持仓","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4585":"ETF&股票定投概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4534":"瑞士信贷持仓","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD"},"translate_title":"辉瑞获得肥胖药物在中国的独家权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1.95},"content_text":"By Tracy Qu \n\n\n \n\n\n  Pfizer has acquired exclusive rights to commercialize an obesity therapy in China in a deal worth up to $495 million. \n\n\n  The U.S. drugmaker reached an agreement with Hangzhou Sciwind Biosciences for ecnoglutide, a drug recently approved by Chinese regulators to treat diabetes, according to a statement posted on WeChat on Tuesday. The therapy is also under regulatory review for obesity treatment, the statement said. \n\n\n  The potential $495 million payment includes an upfront fee as well as regulatory and milestone payments, Sciwind said. \n\n\n  The collaboration with Sciwind \"marks a significant milestone in accelerating Pfizer's long-term strategic footprint in the metabolic field,\" said Pfizer China president Jean-Christophe Pointeau in the statement. \n\n\n  Chinese biotech companies are increasingly partnering with overseas drugmakers. Earlier this month, Innovent Biologics announced a collaboration with Eli Lilly that includes up to $8.5 billion in milestone payments. \n\n\n \n\n\n  Write to Tracy Qu at tracy.qu@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 23, 2026 23:47 ET (04:47 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}